BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

INX-189: Additional Phase Ib data

Additional data from a 2-part, double-blind, dose-escalation, U.S. Phase Ib trial in 67 evaluable treatment-naïve patients with HCV genotype 1 infection showed that once-daily 9, 25, 50 and 100 mg INX-189 reduced median HCV RNA levels from baseline to day 7 by 0.64, 1, 1.47 and 2.53 log10...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >